Meta-analysis of randomised controlled trials of psoriatic arthritis (PsA), characteristics of included patients and major endpoints
| Patients without disease progression at 24 months | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | Total population | Age, mean±SD | % Male | PsA duration, years, mean±SD | % Methotrexate use at baseline | No. of patients with radiographic data | mTSS at baseline, mean±SD | mTSS change at 24months, mean±SD | No. | % | ||
| Posology | TNF blockers | TNF blockers | TNF blockers | TNF blockers | TNF blockers | TNF blockers | TNF blockers | TNF blockers | TNF blockers | |||
| Author, year | Jadad score | Non-biologics | Non-biologics | Non-biologics | Non-biologics | Non-biologics | Non-biologics | Non-biologics | Non-biologics | Non-biologics | ||
| Mease et al, 200617 | 5 | Etanercept | 205 | |||||||||
| 101 | 47.6±ND | 57.0 | 9.0±ND | 42.0 | 71 | 25.9±ND | 64/71 | 90.1 | ||||
| 25 mg 2×/week | 104 | 47.3±ND | 45.0 | 9.2±ND | 41.0 | 70 | 18.3±ND | 48/70 | 68.6 | |||
| Gladman et al, 200718 (ADEPT) | 5 | Adalimumab | 313 | |||||||||
| 151 | 48.5±12.4 | 56.2 | 9.7±8.2 | 51.0 | 144 | 22.6±46.1 | −0.1±ND | 131/145 | 91.0 | |||
| 40 mg/15 day | 162 | 49.1±11.0 | 54.8 | 9.1±8.6 | 50.0 | 152 | 19.1±35.5 | 0.9±ND | 108/153 | 71.1 | ||
| Mease et al, 200919 (ADEPT) | 5 | Adalimumab | 313 | |||||||||
| 151 | 48.6±12.5 | 56.3 | 9.8±8.3 | 51.0 | 115 | 22.7±46.0 | −0.1±1.20 | |||||
| 40 mg/15 day | 162 | 49.2±11.1 | 54.9 | 9.2±8.7 | 50.0 | 128 | 19.2±35.6 | 0.8±2.42 | ||||
| van der Heijde 200720 (IMPACT 2) | 5 | Infliximab | 200 | |||||||||
| 100 | 47.1±12.8 | 71.0 | 8.4±7.2 | 47.0 | 100 | 30.3±61.4 | −0.7±2.53 | 90/100 | 90.0 | |||
| 5 mg/kg/ 8 weeks | 100 | 46.5±11.3 | 51.0 | 7.5±7.8 | 45.0 | 100 | 39.1±82.8 | 0.82±2.62 | 78/100 | 78.0 | ||
| Kavanaugh 201221 (GOREVEAL) | 5 | Golimumab | 405 | |||||||||
| 146 | 45.7±10.7 | 61.0 | 7.2±6.8 | 49.0 | 132 | 23.9±35.4 | −0.16±1.31 | 104/132 | 78.8 | |||
| 50 mg/ 4 weeks | 113 | 47.0±10.6 | 61.0 | 7.6±7.9 | 48.0 | 102 | 18.2±27.8 | 0.27±1.26 | 64/102 | 62.8 | ||
| Golimumab | 405 | |||||||||||
| 146 | 48.2±10.9 | 59.0 | 7.7±7.8 | 47.0 | 137 | 23.4±35.4 | −0.02±1.32 | 105/137 | 76.6 | |||
| 100 mg/ 4 weeks | 113 | 47.0±10.6 | 61.0 | 7.6±7.9 | 48.0 | 102 | 18.2±27.8 | 0.27±1.26 | 64/102 | 62.8 | ||
TNF, tumour necrosis factor; mTSS, modified total Sharp score.